Cardiovascular and Renal Actions of AHR-16303B, an Antagonist of 5-HT2 Receptors and CalciumChannels, in Hypertensive and Nomotensive Rats

Computer-Aided Selection of Potential Antihypertensive Compounds with Dual Mechanism of Action

“…It may be expected that medicines acting simultaneously on different targets will allow physicians to treat patients more flexibly and to decrease the intake of medicines, hence decreasing the side effects.Since the mid-90s, antihypertensive compounds, which act simultaneously on several targets, have been the subject of intensive research, and this led to the discovery of several agents with different dual antihypertensive mechanisms of action. These agents include calcium channel and β 1 adrenergic blockers, calcium channel and α 1 adrenergic blockers, calcium channel blocker and 5HT 2A antagonist, endothelin and angiotensin receptor antagonists, endothelin converting enzyme (ECE) and angiotensin-converting enzyme (ACE) inhibitors, and NEP and ECE inhibitors. , Dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase have proved to be promising compounds for the treatment of cardiovascular diseases. , The clinical study of omapatrilat and sampatrilat shows that these dual ACE/NEP inhibitors are more potent in the treatment of hypertension and chronic heart failure than ACE inhibitor monotherapy like lisinopril.…”